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medication upon discontinuing clopidogrel. CONCLUSION:
Clopidogrel was the dominant oral antiplatelet by market share.
These patients also used signiﬁcant pharmacy resources on other
medications. While average duration was largely consistent with
treatment guidelines, variations in individual treatment length
were detected. This ﬁnding suggests inconsistencies in utilization
versus treatment guidelines. Early discontinuation of cardiac
medications in some patients also raises concern.
PCV34
COST OF CONSUMABLES ASSOCIATED WITH
CARDIOVASCULAR COMPUTED TOMOGRAPHY
ANGIOGRAPHY:THE CARDIOLOGIST’S PERSPECTIVE
Vishalpura T1, Callister TQ2, Sarnes MW3
1Xcenda,Yardley, PA, USA, 2Tennessee Heart and Vascular Institute,
P.C, Hendersonville,TN, USA, 3Xcenda, Palm Harbor, FL, USA
OBJECTIVES: Computed tomography angiography (CTA) scan-
ners have advanced patient care by providing cardiologists with
the latest in imaging technology. When deciding to purchase a
CTA scanner, practices must evaluate the economic feasibility of
ownership in terms of both ﬁxed (eg, equipment and facility
costs) and variable costs (ie, consumables costs). The objective
of this study was to provide cardiology practices with a com-
prehensive cost estimate for the cost of consumables incurred for
CTA procedure. METHODS: Practice patterns from a large car-
diology practice were evaluated for all CTA procedures over an
eight-month timeframe. The various consumables utilized for
CTA procedures were captured and classiﬁed into three main cat-
egories: contrast media, drugs, and medical supplies. The average
utilization of each consumable was then evaluated, and the unit
acquisition cost for each consumable was applied to quantify the
average cost of consumables per CTA procedure. RESULTS:
From January 2006 through August 2006, data from 3119 pro-
cedures were evaluated. The average cost of consumables per
procedure incurred by the practice was $83.31. Of this cost,
$32.55 was incurred for contrast medium. Additionally, $9.91
was the average cost per procedure incurred for drugs such as
beta blockers, solu-medrol, diphenhydramine, intravenous
ﬂuids, nitrolingual spray, and antiemetics. The largest compo-
nent of consumables was medical supplies (eg, syringes, needles,
tubing, cannulae, intravenous catheter, dressing/bandages, table
paper, gloves, alcohol pads, etc), which cost the institution an
average of $40.85 per procedure. CONCLUSION: When evalu-
ating the economic feasibility of operating a CTA scanner, car-
diology practices can expect to incur an average of $83.31 per
procedure for consumables.
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OBJECTIVES: Compare impact of nesiritide (a recombinant
natriuretic peptide approved for intravenous treatment of
ADHF) administration within ﬁrst day versus after ﬁrst day on
in-hospital outcomes using an inpatient claims database of 400+
US hospitals and 600,000+ discharges (PREMIER). METHODS:
From 681,690 discharges during 2003 and 2004 in the
PREMIER database, we studied patients with DRG 127 at dis-
charge and ICD 9 codes for primary diagnosis of CHF. First day
nesiritide (D1) was deﬁned as nesiritide + diuretic administration
within 1st day of hospital admission; post-ﬁrst-day administra-
tion (post-D1) was deﬁned as nesiritide administration after ﬁrst
hospital day with diuretic therapy during ﬁrst day. Four out-
comes variables were analyzed: discharge status, hospital and
ICU LOS, and hospitalization cost. Propensity matching and
propensity covariate adjustments were performed in all regres-
sion analyses to remove bias in between-group comparisons.
RESULTS: In all, 8126 patient discharge episodes were identi-
ﬁed as D1 and 793 as post-D1. The D1 group had reduced mor-
tality odds versus post-D1 (0.46, 95% CI: 0.36, 0.59, P <
0.0001). Hospital and ICU LOS were shorter for D1 versus post-
D1 (−4.5 days [95% CI: −4.9, −4.2, P < 0.0001] and −1.7 days
[95% CI: −2, −1.5, P < 0.0001], respectively). Hospital costs
were lower for D1 patients (D1-Post D1): −$6642 (95% CI: 
−$7226, −$6058, P < 0.0001). Adjusted and unadjusted analy-
ses on all four outcomes were consistent and achieved statistical
signiﬁcance. CONCLUSION: This analysis demonstrated that in
two groups of propensity-matched hospitalized patients, those
treated with nesiritide within the ﬁrst day of hospital admission
have better outcomes than those treated with nesiritide later.
These ﬁndings are based on retrospective data sources. A recently
announced prospective randomized, controlled global clinical
trial enrolling 7000+ patients (ASCEND-HF) will provide addi-
tional information.
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OBJECTIVES: To study the effects of two sequential changes in
drug cost-sharing policies on adherence to statins and beta-
blockers by seniors in British Columbia. METHODS: For each
drug class, we identiﬁed a baseline cohort of subjects initiating
therapy in the 6 months prior to January 1, 2001, a co-payment
cohort initiating therapy in the 6 months prior to the co-payment
policy introduced January 1, 2002, and a co-insurance cohort
initiating therapy in the 6 months prior the co-insurance policy
introduced May 1, 2003. We calculated the proportion of
patients adherent in each cohort each month, with follow-up for
each cohort beginning at the start of that cohort’s recruitment
period and ending 15 months later. Patients were deﬁned as
adherent during a month if they had a proportion of days
covered (PDC) of 80% or greater, calculated by dividing the
number of days the patient had drug supply available by the
number of cohort membership days the patient contributed in
that calendar month. RESULTS: In the baseline cohort, which
did not experience cost-sharing, 55.8% of statin initiators were
adherent to their statins at month 15. The adherence level in the
co-payment cohort at this time, 9 months after the introduction
of the co-payment policy, was 50.5%. 50.8% of co-insurance
cohort member were adherent. Adherence to beta-blockers was
lower, with 48% of the baseline cohort initiators adherent at
month 15. However, the introduction of the co-payment and co-
insurance policies reduced this adherence level by only 1 per-
centage point. CONCLUSION: The introduction of the
co-payment and co-insurance policies reduced adherence to
statins by 5 percentage points relative to baseline levels, but had
a much smaller effect on beta blocker adherence levels. Policy-
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makers should consider drug cost as a potential modiﬁer of
policy effects.
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OBJECTIVES: Each year 500,000 Canadians are hospitalized
and 79,000 die due to cardiovascular disease (CVD). Strong evi-
dence supports the use of “triple” therapy with ASA, statin, and
angiotension converting enzyme inhibitors (ACEi) in patients
with CVD or diabetes; however current care only partially
reﬂects this evidence. The objective was to quantify the reduc-
tion in CV events (MI, stroke, CHD/stroke death) with triple
therapy compared to current care in high-risk patients over the
age of 50. METHODS: Patients at high risk (either diabetes,
prior myocardial infarct and/or stroke) were included. Canadian
Community Health Survey (CCHS) data for 2003 were used to
estimate prevalence of disease, which was applied to the age-spe-
ciﬁc population in Canada in order to calculate the total number
of high risk patients. Event risk was calculated based on the
Framingham risk equations. Current use of triple therapy was
derived from a Canadian registry of high risk patients (n =
5,095). Values for risk factors were based on the CCHS and the
registry. A relative risk reduction of 54% for all events was
assumed for triple therapy compared to no treatment, based on
trial data. RESULTS: Current usual care has reduced the number
of cardiovascular events from an estimated 1.01 M to just over
600,000 over the next 10 years. However, of the 2.2 million high
risk patients, approximately 64% of them do not receive triple
combination therapy. It is estimated that an additional 143,041
cardiovascular events, including 37,703 cardiovascular deaths,
could be prevented over the next ten years by treating all high
risk Canadians over the age of 50 years with triple combination
therapy. CONCLUSION: Canadian physicians have done well
in reducing the burden of CVD. More optimal guidelines based
management of high risk patients can signiﬁcantly reduce CVD
mortality and morbidity and must be strongly encouraged.
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OBJECTIVES: Little is known about treatment of depression in
coronary artery disease (CAD) at ambulatory visits in United
States. METHODS: Retrospective analyses were conducted of
the combined 5-year data (2000–2004) of physician ofﬁce-based
National Ambulatory Medical Care Survey (NAMCS) and out-
patient and emergency department based National Hospital
Ambulatory Medical Care Survey (NHAMCS). Visits with coro-
nary artery disease (ICD-9-CM 410–414) and depression disor-
der (296, 311) were identiﬁed. The visits combined across the
three settings were classiﬁed into CAD visits with and without
depression. Sample estimates were weighted and projected to the
population with 95% conﬁdence intervals. Multivariate logistic
regression was used to determine signiﬁcant characteristics of
antidepressant treatment mention at visits. RESULTS: About
1.23 million ambulatory visits or 0.79% (95%CI: 0.51–1.21) of
all adult CAD associated visits also had a diagnosis of depres-
sion. Antidepressant medication (TCA, MAOI, SSRI, or bupro-
prion) was associated with 7.75% (95%CI: 6.49–9.24) of all
CAD associated visits with SSRI being associated with about
5.46% of visits. In multivariate logistic-regression analysis, male
gender (adjusted odds-ratio, OR, 0.47, 95%CI: 0.33–0.68), race
other than Caucasian (OR, 0.38, 95%CI: 0.21–0.69), emergency
department (ED) setting (OR, 0.32, 95%CI: 0.21–0.50),
decreased the likelihood while recent years (2002–04) (OR, 1.42,
95%CI: 1.03–1.96), depression (OR, 7.92, 95%CI: 1.56–40.42),
and any mental health disorder (OR, 4.60, 95%CI: 1.74–12.14),
and number of medications (OR, 6.27, 95%CI: 3.93–9.99) sig-
niﬁcantly increased the likelihood of an antidepressant medica-
tion at CAD associated visits. CONCLUSION: About 1% and
7.75% of CAD visits were associated with depression, and
included antidepressants, respectively. Further research is needed
on the less likelihood of antidepressant treatment at visits by
male and other ethnic minority patients, and in the ED setting
with a diagnosis of CAD.
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OBJECTIVES: To determine the trend for off-label prescribing
of statins from 1998 to 2004 and to explore the different con-
ditions in which statins are being prescribed off-label. We also
sought to determine the proportion of off-label use for experi-
mental conditions (Alzheimer’s disease, Multiple Sclerosis,
Rheumatoid Arthritis, selected Cancers). METHODS: This
study analyzed the National Ambulatory Medical Care Survey
(NAMCS) and the National Hospital Ambulatory Medical Care
Survey (NHAMCS) from 1998 through 2004. The NAMCS and
NHAMCS are nation-wide surveys of non-federal physicians,
hospital out-patient, and emergency departments. Statin visits
were identiﬁed using generic drug codes for all marketed statins
in the U.S. On-label statin use was deﬁned as a visit that had a:
primary or secondary ICD-9-CM code or reason for visit code
for dyslipidemias, Acute Myocardial Infarction, Ischemic Heart
Disease, Angina, Atherosclerosis, or a lipid lab test, or a CPT-4
code for a revascularization procedure. Sampling weights were
used to provide national estimates. RESULTS: In 1998, there
were a total of 24.8 million (95% CI: 20,883,228–28,784,766)
ambulatory visits resulting in a statin prescription of which 37%
were off-label. In 2004 there were 61.2 million (95% CI:
52,782,456–69,673,240) statin visits and 47% were off-label.
The most common diagnoses associated with off-label statin
visits in 2004 were hypertension (26%) and diabetes (20%). A
total of 2.6% of off-label statin visits had a diagnosis of osteo-
porosis, and 1.7%, 0.5%, 0.09%, and 0.04% had cancer,
Alzheimer’s disease, multiple sclerosis, and rheumatoid arthritis
respectively. CONCLUSION: The prescribing of statins has
grown dramatically over the past seven years and the proportion
of uses without a supporting diagnosis has grown modestly from
37% to 47%. Most of the off-label visits 1998 through 2004 are
for persons diagnosed with hypertension and diabetes. Use of
statins for experimental purposes appears to be negligible.
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